The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (MK-3475) for previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase II KEYNOTE-180 study.
 
Manish A. Shah
Consulting or Advisory Role - Lilly
Research Funding - Genentech (Inst); Sanofi (Inst)
 
Jaafar Bennouna
Honoraria - Boehringer Ingelheim; Novartis; Pierre Fabre; roche
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pierre Fabre; Roche
 
Lin Shen
No Relationships to Disclose
 
Peter C. Enzinger
No Relationships to Disclose
 
Qiao Li
No Relationships to Disclose
 
Ildiko Csiki
No Relationships to Disclose
 
Minori Koshiji
No Relationships to Disclose
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly Japan; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)